some of those posts may be from a bot. Others are active responses that can't be programmed. yeah, pretty sick, juvenile trash.
look, I hope you're right but i'm a tad superstitious and your comment is the one fear I have now. Never underestimate the blatant manipulation of share price by the holders of the converts - these guys are powerful and may act in concert knowing SEC will never do anything.
EXEL is on a tear but hitting $8-$9 doesn't mean it can't drop back below $7.
"High enough that the converts cant pull it down anymore..."
talk like that almost ensures share price will drop below $6.90 around August some time
Snow - Dow lost ~ 100 points in last 30minutes of trading today. Decrease in EXEL sp mirrored Dow.
What was that all about? Do you know? Any ideas?
any stipulation they could do both? repurchase some and issue fewer shares to cover the rest? seems like a huge block of cash or stock to be binary.
"..... EXEL management has to finally "show us the money..."
there was an interview with Papadapolous a year or two ago where he used similar language describing EXEL's state of affairs - something like lots of promise but nothing proven. Now there is proof and one would hope Papadapolous and the rest of BOD had something to do with MMM changing from "getting the band back together" to in-license compounds. It's time to get cabo in the hands of a BigPharm where it can be fully and rapidly developed into it's full potential. There's too much competition to wait for revenues to kick in to start more trials. EXEL has already missed too many opportunities.
payload Abs are extremely tricky. Besides issues with linker, the Ab binding site has to induce internalization of the target and needs to be in a very narrow avidity range. Many Abs bind to target and don't induce internalization. Ab will dissociate from it's target if it binds too loosely and remains bound to it's target if it binds too tightly. An Ab that doesn't dissociate from it's target is recycled to to cell surface and doesn't make it to endosomal compartments where acidic environment is needed to break down the linker. Then there issues with specific targets...
IMGN must have learned a lot since 2010 since Kadcyla appears to be effective but other receptor targets will not behave as well and issues with Ab, linker and target remain. Hard to predict if they will be successful given they are entering "convertible purgatory".
"...they just can't seem to get lucky again..."
one of the BigPharms I was with had a collaboration w IMGN ~ 2010. We worked with one of their payload antibodies and could show no difference between the immuno-conjugate and naked toxin (maytansinoid) using in-vitro proliferation and cell-killing assays. There was clearly a problem with the linker connecting the toxin with the antibody. They claimed it worked great in murine models.
today's data release is huge for, as you say, patients and Ariad. there's been no discussion on this mb - what a waste. posters burying relevant news with their junk on this mb should be ashamed.